Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.35 SEK | +0.17% | +0.17% | +2.53% |
05-02 | Transcript : Vimian Group AB, Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Vimian Group AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 502.65 and 254.19 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 43.91 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.53% | 1.44B | - | ||
-9.60% | 6.48B | B- | ||
+24.75% | 3.7B | B- | ||
-3.20% | 3.1B | B- | ||
-15.13% | 1.37B | B | ||
-25.63% | 1.24B | C- | ||
-6.64% | 1.19B | - | ||
-10.84% | 1.17B | - | ||
-.--% | 1.05B | - | ||
-7.56% | 819M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VIMIAN Stock
- Ratings Vimian Group AB